Total Payments
$810,297
2024 Payments
$59,535
Companies
39
Transactions
1,736
Medicare Patients
2,499
Medicare Billing
$4.7M
Payment Breakdown by Category
Other$629,977 (77.7%)
Travel$101,242 (12.5%)
Food & Beverage$35,316 (4.4%)
Consulting$34,157 (4.2%)
Research$9,000 (1.1%)
Education$605.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $629,152 | 336 | 77.6% |
| Travel and Lodging | $101,242 | 283 | 12.5% |
| Food and Beverage | $35,316 | 1,078 | 4.4% |
| Consulting Fee | $34,157 | 21 | 4.2% |
| Unspecified | $9,000 | 2 | 1.1% |
| Honoraria | $825.00 | 1 | 0.1% |
| Education | $605.62 | 15 | 0.1% |
Payments by Type
General
$801,297
1,734 transactions
Research
$9,000
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $174,005 | 296 | $0 (2024) |
| ABBVIE INC. | $140,272 | 302 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $129,503 | 122 | $0 (2024) |
| Lilly USA, LLC | $91,088 | 151 | $0 (2024) |
| Janssen Biotech, Inc. | $55,192 | 97 | $0 (2024) |
| Celgene Corporation | $51,655 | 110 | $0 (2019) |
| Genentech USA, Inc. | $45,371 | 117 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $38,724 | 75 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $35,696 | 77 | $0 (2024) |
| GENZYME CORPORATION | $20,769 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,535 | 176 | Janssen Biotech, Inc. ($15,890) |
| 2023 | $101,247 | 187 | Janssen Biotech, Inc. ($32,155) |
| 2022 | $113,906 | 205 | Amgen Inc. ($31,755) |
| 2021 | $64,172 | 57 | Janssen Scientific Affairs, LLC ($35,561) |
| 2020 | $61,418 | 115 | Lilly USA, LLC ($22,149) |
| 2019 | $145,461 | 378 | Amgen Inc. ($29,137) |
| 2018 | $139,230 | 319 | Janssen Scientific Affairs, LLC ($30,512) |
| 2017 | $125,328 | 299 | AbbVie, Inc. ($24,171) |
All Payment Transactions
1,736 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $497.16 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $64.41 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $23.91 | General |
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $38.85 | General |
| Category: Immunology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $35.18 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Biocon Biologics Inc | Hulio (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Rheumatology | ||||||
| 12/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $657.74 | General |
| 12/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Analgesic | ||||||
| 12/03/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Bone Health | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $28.84 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $5.43 | General |
| Category: Immunology | ||||||
| 11/17/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 11/16/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | Cash or cash equivalent | $75.04 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 11/14/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,475.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $8.88 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/13/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: Analgesic | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $850.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | PFIZER INC. | $9,000 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 734 | 88,907 | $3.6M | $1.3M |
| 2022 | 10 | 583 | 42,796 | $2.7M | $1.0M |
| 2021 | 11 | 648 | 41,921 | $2.7M | $1.2M |
| 2020 | 10 | 534 | 38,849 | $2.5M | $1.2M |
Total Patients
2,499
Total Services
212,473
Medicare Billing
$4.7M
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 30 | 19,500 | $1.3M | $656,243 | 51.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 31 | 24,900 | $992,000 | $261,600 | 26.4% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 12 | 37,160 | $302,680 | $172,491 | 57.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 17 | 5,200 | $598,000 | $126,703 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 184 | 378 | $83,940 | $36,774 | 43.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 95 | 586 | $250,350 | $32,462 | 13.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 178 | 286 | $42,900 | $19,857 | 46.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $17,400 | $6,598 | 37.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 22 | 155 | $19,500 | $2,713 | 13.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 99 | $17,325 | $1,185 | 6.8% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 93 | 585 | $8,775 | $298.31 | 3.4% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 29 | 18,300 | $1.2M | $632,768 | 53.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 24 | 19,150 | $766,000 | $225,993 | 29.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 13 | 3,720 | $427,800 | $105,358 | 24.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 81 | 492 | $196,800 | $29,634 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 121 | 196 | $39,200 | $19,872 | 50.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 161 | 276 | $41,400 | $19,120 | 46.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $14,100 | $6,288 | 44.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 17 | 109 | $10,900 | $2,008 | 18.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 16 | 17 | $2,550 | $1,245 | 48.8% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 74 | 489 | $7,335 | $256.59 | 3.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 30 | 16,200 | $1.1M | $660,348 | 62.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2021 | 21 | 19,400 | $776,000 | $266,952 | 34.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 15 | 4,660 | $535,900 | $152,255 | 28.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 183 | 331 | $49,650 | $22,853 | 46.0% |
About Dr. Robert Schoen, MD
Dr. Robert Schoen, MD is a Rheumatology healthcare provider based in Guilford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689652208.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Schoen, MD has received a total of $810,297 in payments from pharmaceutical and medical device companies, with $59,535 received in 2024. These payments were reported across 1,736 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($629,152).
As a Medicare-enrolled provider, Schoen has provided services to 2,499 Medicare beneficiaries, totaling 212,473 services with total Medicare billing of $4.7M. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Guilford, CT
- Active Since 01/04/2006
- Last Updated 06/19/2025
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1689652208
Products in Payments
- SIMPONI ARIA (Biological) $98,527
- Otezla (Drug) $91,683
- Enbrel (Biological) $82,575
- TALTZ (Drug) $56,743
- STELARA (Biological) $52,572
- KEVZARA (Biological) $37,360
- RINVOQ (Biological) $34,022
- TREMFYA (Drug) $33,411
- OLUMIANT (Drug) $27,373
- SKYRIZI (Biological) $24,769
- Actemra (Biological) $23,597
- Humira (Biological) $22,515
- ORENCIA (Biological) $22,214
- KEVZARA SARILUMAB INJECTION (Biological) $18,057
- Rituxan (Biological) $17,406
- Rinvoq (Biological) $16,824
- TAVNEOS (Drug) $12,807
- Tavneos (Drug) $8,997
- RINVOQ (Drug) $7,418
- Cimzia (Drug) $2,221
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.